Morgan Stanley Reiterates Buy Rating on Disc Medicine, Inc.

Morgan Stanley has reiterated its buy rating on Disc Medicine, Inc. (NasdaqGM: IRON), setting a price target of $85. This assessment was made on June 16, 2026, with shares trading at $70.09.

What Changed in Morgan Stanley's Disc Medicine Position

Morgan Stanley's analyst Sean Laaman maintained a buy rating on Disc Medicine, Inc., suggesting confidence in the company's future prospects with a price target of $85. This reiteration comes as the stock was trading near $70.09.

Other Institutional Activity in Disc Medicine

FMR LLC increased its holdings by 136,672 shares, ending with approximately 5.59 million shares valued at $357.23 million. RA Capital Management, L.P. boosted its position significantly by 474,089 shares to hold about 2.45 million shares worth $156.67 million. Meanwhile, BlackRock, Inc. slightly trimmed its stake by 1,149 shares, maintaining around 2.27 million shares valued at $145.39 million. Wellington Management Group LLP added 217,102 shares, bringing its total to 1.74 million shares worth $110.96 million. State Street Corp also increased its position by 510,253 shares, resulting in 1.70 million shares valued at $108.59 million.

Disc Medicine, Inc. Stock Snapshot

Shares of Disc Medicine, Inc. (NasdaqGM: IRON) traded at $70.09. The company has a market cap of about $2.68 billion and a forward P/E ratio, which isn't meaningful due to its lack of profitability. It has a beta of 2.101, indicating higher volatility compared to the market. The 52-week range for the stock is between $40.00 and $99.50, with a 50-day moving average of $68.31 and a 200-day moving average of $73.01. The company has strong liquidity with a current ratio of 24.002 and a quick ratio of 23.446, alongside a debt-to-equity ratio of 4.512.

Insider Buying and Selling at Disc Medicine, Inc.

Recent insider transactions include planned sales by Chief Financial Officer Jean Franchi, who sold shares on multiple occasions in early 2026, including 6,257 shares on April 14 at an average price of $69.24. Chief Medical Officer William Jacob Savage also reported sales, including 5,731 shares on April 13 at an average price of $66.38.

Analysts Set New Price Targets

On June 16, 2026, Morgan Stanley maintained its buy rating for Disc Medicine with a price target of $85. Other firms like Wells Fargo and Truist Securities have also maintained buy ratings with targets of $79 and $83, respectively. The consensus among 11 analysts is a strong buy, with a mean target price of $101.09.

About Disc Medicine, Inc.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing treatments for serious blood disorders. The company is working on several clinical and preclinical candidates aimed at modifying biological pathways related to red blood cell formation. Its pipeline includes treatments for conditions like erythropoietic protoporphyria and anemia associated with various diseases. Founded in 2017, the company is led by CEO Dr. John D. Quisel.

Bottom Line

Morgan Stanley's reiteration of a buy rating with an $85 target shows continued confidence in Disc Medicine, Inc. Investors track these updates for insights into the company's prospects. It's important to note that analyst ratings are based on past data and may not reflect the current market situation.